Indication
Relapsing-remitting multiple sclerosis
Aliases
Relapsing Multiple Sclerosis
4 clinical trials
9 products
Product
EvobrutinibClinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 With a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients With Relapsing Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity.Status: Terminated, Estimated PCD: 2018-01-24
Product
PlaceboProduct
TecfideraProduct
CT-P53Clinical trial
A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 1/3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple SclerosisStatus: Not yet recruiting, Estimated PCD: 2027-02-01
Product
EU-OcrevusProduct
US-OcrevusClinical trial
A Prospective Randomized Trial of Non-inferiority Comparing RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple SclerosisStatus: Recruiting, Estimated PCD: 2030-03-31
Product
RituximabProduct
OcrelizumabClinical trial
Optical Coherence Tomography as a Measure of Neuroprotection in Patients With Relapsing-Remitting Multiple Sclerosis Receiving Natalizumab or Interferon Beta-1aStatus: Withdrawn, Estimated PCD: 2009-08-01
Product
TYSABRI